Indaptus Therapeutics (INDP) Expected to Announce Quarterly Earnings on Thursday

Indaptus Therapeutics (NASDAQ:INDP) is anticipated to announce its results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($4.36) per share for the quarter.

Indaptus Therapeutics Stock Up 1.1%

Shares of Indaptus Therapeutics stock opened at $1.87 on Tuesday. The company has a market cap of $4.19 million, a P/E ratio of -0.06 and a beta of 0.97. The firm’s 50 day moving average price is $2.32 and its 200-day moving average price is $2.89. Indaptus Therapeutics has a 52-week low of $1.52 and a 52-week high of $47.60.

Institutional Trading of Indaptus Therapeutics

An institutional investor recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC purchased a new stake in Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 1.72% of Indaptus Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 7.06% of the company’s stock.

Analyst Upgrades and Downgrades

INDP has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Indaptus Therapeutics in a research note on Thursday, January 22nd. Wall Street Zen lowered Indaptus Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 6th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.